Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

646
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
646
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

661
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
661
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

382
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
382
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

866
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
866

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease-directed progress.

British journal of haematology·2026
Same author

Accuracy of Diagnosis in Myeloproliferative Neoplasms With Splanchnic Vein Thrombosis (MPN-SVT).

American journal of hematology·2026
Same author

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

British journal of haematology·2026
Same author

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Blood advances·2026
Same author

Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis.

Cancer medicine·2026
Same author

Combination treatments for myelofibrosis in JAK inhibitor-naive patients: evidence, rationale, and clinical direction.

Expert opinion on pharmacotherapy·2026

Related Experiment Video

Updated: Mar 31, 2026

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

11.1K

How we diagnose and treat essential thrombocythaemia.

Samah Alimam1, Bridget S Wilkins2, Claire N Harrison1

  • 1Department of Haematology, Guy's & St Thomas' Hospitals NHS Foundation Trust, Guy's Hospital, London, UK.

British Journal of Haematology
|October 15, 2015
PubMed
Summary

Essential thrombocythaemia (ET) diagnosis and management are evolving due to molecular biology advances and clinical data. Current treatment focuses on careful diagnosis and cytoreductive therapy for select patients with ET.

Keywords:
CALRJAK2essential thrombocythaemiathrombocytosis

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

7.9K

Related Experiment Videos

Last Updated: Mar 31, 2026

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

11.1K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

7.9K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Essential thrombocythaemia (ET) management strategies are evolving.
  • Advances in molecular biology and clinical data influence diagnostic and treatment approaches.
  • Recognition of ET-associated symptoms and management options is increasing.

Purpose of the Study:

  • To review current diagnostic and management strategies for essential thrombocythaemia (ET).
  • To highlight the evolving landscape of ET treatment based on recent scientific advancements.
  • To present a case-based approach to illustrate management decisions in ET.

Main Methods:

  • Review of recent literature on essential thrombocythaemia (ET).
  • Analysis of clinical trial data and retrospective patient cohort studies.
  • Case-based format to demonstrate practical management strategies.

Main Results:

  • Diagnosis and management of ET are significantly influenced by molecular biology insights.
  • Clinical management options for ET have remained relatively stable, but treatment targets are shifting.
  • Improved recognition of ET symptoms and emerging management options are noted.

Conclusions:

  • Judicious diagnosis is crucial for successful essential thrombocythaemia (ET) management.
  • Cytoreductive therapy is indicated for a subset of ET patients.
  • The evolving understanding of ET necessitates adaptive management strategies.